Evaluation of N-(phenylmethyl)-4-[5-(phenylmethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-4-yl]benzamide inhibitors of Mycobacterium tuberculosis growth

Michael D Wall; Michael Oshin; Gavin A C Chung; Tony Parkhouse; Andrea Gore; Esperanza Herreros; Brian Cox; Ken Duncan; Brian Evans; Martin Everett; Alfonso Mendoza

doi:10.1016/j.bmcl.2007.02.078

Evaluation of N-(phenylmethyl)-4-[5-(phenylmethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-4-yl]benzamide inhibitors of Mycobacterium tuberculosis growth

Bioorg Med Chem Lett. 2007 May 15;17(10):2740-4. doi: 10.1016/j.bmcl.2007.02.078. Epub 2007 Mar 3.

Authors

Michael D Wall¹, Michael Oshin, Gavin A C Chung, Tony Parkhouse, Andrea Gore, Esperanza Herreros, Brian Cox, Ken Duncan, Brian Evans, Martin Everett, Alfonso Mendoza

Affiliation

¹ GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK. michael.d.wall@gsk.com

PMID: 17418567
DOI: 10.1016/j.bmcl.2007.02.078

Abstract

The biological evaluation of imidazopiperidines as FAS II inhibitors of Mycobacterium tuberculosis growth has been carried out with a view to assessment of potential as lead compounds for the development of a new TB drug. A summary of the hit evaluation and current challenges is described herein.

Publication types

Evaluation Study

MeSH terms

Anti-Bacterial Agents / chemistry
Anti-Bacterial Agents / pharmacology*
Benzamides / chemistry
Benzamides / pharmacology*
Microbial Sensitivity Tests
Molecular Structure
Mycobacterium tuberculosis / drug effects*
Piperidines / chemistry
Piperidines / pharmacology*
Structure-Activity Relationship

Substances

Anti-Bacterial Agents
Benzamides
Piperidines